NDLI: Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients

Content Provider	Springer Nature : BioMed Central
Author	Capone, Mariaelena Fratangelo, Federica Giannarelli, Diana Sorrentino, Claudia Turiello, Roberta Zanotta, Serena Galati, Domenico Madonna, Gabriele Tuffanelli, Marilena Scarpato, Luigi Grimaldi, Antonio M. Esposito, Assunta Azzaro, Rosa Pinto, Antonio Cavalcanti, Ernesta Pinto, Aldo Morello, Silvana Ascierto, Paolo A.
Abstract	Background PD-1 blocking agents, such as nivolumab, have demonstrated clear anti-tumor effects and clinical benefits in a subset of patients with advanced malignancies. Nonetheless, more efforts are needed to identify reliable biomarkers for outcome, to correctly select patients who will benefit from anti-PD-1 treatment. The aim of this study was to investigate the role of peripheral CD8+T cells expressing CD73, involved in the generation of the immune suppressive molecule adenosine, in predicting outcome after nivolumab treatment in advanced melanoma patients. Methods PBMCs from 100 melanoma patients treated with nivolumab were collected at National Cancer Institute “G. Pascale” of Naples. Frequencies of CD8+ lymphocytes phenotypes were assessed by flow cytometry at baseline before nivolumab treatment, along with clinical characteristics and blood count parameters. Healthy controls (n = 20) were also analysed. Percentages of baseline T cells expressing PD-1 and CD73 were correlated with outcome after nivolumab treatment. Results Melanoma patients presented a lower frequency of total circulating CD8+ lymphocytes than control subjects (p = 0.008). Patients with low baseline percentage of circulating CD8+PD-1+CD73+ lymphocytes (< 2.3%) had better survival (22.4 months vs 6.9 months, p = 0.001). Patients (39%) with clinical benefit from nivolumab therapy presented a significantly lower frequency of circulating CD8+PD-1+CD73+ lymphocytes than patients who progressed to nivolumab treatment (p = 0.02). Conclusions Our observations suggest that baseline CD73 expression on circulating CD8+PD-1+ lymphocytes appear a promising biomarker of response to anti-PD-1 treatment in melanoma patients. Further investigations are needed for validation and for clarifying its role as prognostic or predictive marker.
Related Links	https://translational-medicine.biomedcentral.com/counter/pdf/10.1186/s12967-020-02285-0.pdf
Ending Page	10
Page Count	10
Starting Page	1
File Format	HTM / HTML
ISSN	14795876
DOI	10.1186/s12967-020-02285-0
Journal	Journal of Translational Medicine
Issue Number	1
Volume Number	18
Language	English
Publisher	BioMed Central
Publisher Date	2020-03-11
Access Restriction	Open
Subject Keyword	Biomedicine Medicine Public Health Immunotherapy Nivolumab Metastatic melanoma CD73 Circulating CD8+ lymphocytes Medicine/Public Health
Content Type	Text
Resource Type	Article
Subject	Biochemistry, Genetics and Molecular Biology Medicine
Journal Impact Factor	6.1/2023
5-Year Journal Impact Factor	6.3/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab

Potential clinical implications of CD4+CD26high T cells for nivolumab treated melanoma patients

The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab

Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy

Dynamic evolution and antitumor mechanisms of CXCR6+CD8+ T cells in small cell lung cancer treated with low-dose radiotherapy and immunotherapy

Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients

A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab

Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm

The prognostic role of circulating CD8+ T cell proliferation in patients with untreated extensive stage small cell lung cancer

Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients

Similar Documents

Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab

Potential clinical implications of CD4+CD26high T cells for nivolumab treated melanoma patients

The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab

Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy

Dynamic evolution and antitumor mechanisms of CXCR6+CD8+ T cells in small cell lung cancer treated with low-dose radiotherapy and immunotherapy

Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients

A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab

Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm

The prognostic role of circulating CD8+ T cell proliferation in patients with untreated extensive stage small cell lung cancer

Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients